Email
Print
Vulvodynia Treatment Market - Forecast(2024 - 2030)
Vulvodynia Treatment Market Overview
Vulvodynia Treatment Market size is estimated to reach $77.4 billion by 2027, growing at a CAGR of 9.8% during the forecast period 2022-2027. Vulvodynia or Vulval Pain is defined as the incomprehensible long-standing discomfort/ache around the genital part of women. Vulval aching turns many women aversive towards some activities like desk bounding for too long and involving intimacy as these activities intensify the agony. A few primary reasons contributing to vulval aching are neuropathic complications (=any injury in the part), Sjogren’s Syndrome (=Dryness and Stiffness in muscles around genitals, Chronic pain syndrome, Genetic predisposition). Moreover, Cotton Swab Testing, Botulinum Toxin are common procedures available in the market to cure the root cause of such problems i.e., Stiffness and Dryness. Complications like these have come to the foreground in recent years on an unprecedented scale as a result of the modern lifestyle. Intensification in Vulval pain cases, an innumerable amount of spending by countries into research and development are set to drive the growth of the Vulvodynia Treatment Industry for the period 2022-2027.
Report Coverage
The report: “Vulvodynia Treatment Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Vulvodynia Treatment Market.
By Drug Type: SNRI (=serotonin-norepinephrine reuptake inhibitors), Anesthetic, Anticonvulsants, Nerve Block, Tricyclic Antidepressants, local anesthetics, Hormone creams, Antimicrobials.
By Buyers/End User: Hospitals, Health Centers, local medical stores, retail Pharmacies, Online pharmacies.
By Administrable Mode: External mode/Topical, Oral, and Injectable
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).
Key Takeaways:
- Geographically, the North America Vulvodynia Treatment Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the rise in cases of women inflicted with vulval pain, commonness, and pleasantness in discussing such questions and problems in the public forum.
- The increase in the cases of patients inflicted with vulval pain is driving the Vulvodynia Treatment Market. However, truncated consciousness with regard to sickness is one of the major factors that are said to reduce the growth of the Vulvodynia Treatment Market.
- Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Vulvodynia Treatment Market report.
Vulvodynia Treatment Market Share, By Geography, 2021(%)
For more details on this report - Request for Sample
Vulvodynia Treatment Market Segment Analysis-By Drug Type
The Vulvodynia Treatment Market based on the Drug Type can be further segmented into SNRI (=serotonin-norepinephrine reuptake inhibitors), Anesthetic, Anticonvulsants, Nerve Block, Tricyclic Antidepressants, local anesthetics, Hormone creams, Antimicrobials. The Anticonvulsant segment held the largest share in 2021 owing to the factors such as ballooning usage in the treatment of vulval pain. Especially, gabapentin is the most prescribed anticonvulsant medication for curing vulvodynia. It is widely prescribed by medical practitioners and doctors because of its effectiveness along with low to moderate side effects. In addition to that, enlarging efforts and capital expenditure in the research and development of new drugs also fuel the growth of the anticonvulsant drug segment.
However, both the Anticonvulsant and Tricyclic Antidepressants segment is estimated to be the fastest-growing segment with a CAGR of 10.3% over the period 2022-2027. This growth is owing to its expanding role as a pain reliever. Gabapentin, an anticonvulsant has been a primary medication for treating persistent vulvar pain, and moreover, the American College of Obstetricians and Gynecologists recommend the usage of such medication.
Vulvodynia Treatment Market Segment Analysis-By End-User
The Vulvodynia Treatment Market based on the End User can be further segmented into Hospitals, Health Centers, local medical stores, retail Pharmacies, Online pharmacies. The Hospital segment held the largest share in 2021 owing to the factors such as hospitals which are the first point of contact for patients worldwide. The expanding cases of vulvodynia, improvements in health infrastructure in developing ad developed nations, the innumerable flow of hard cash into research, and developments of drugs and medicines are steering the market.
The online pharmacy segment is estimated to be the fastest-growing segment with a CAGR of 10.4% over the forecast period 2022-2027. This growth is owing to ballooning digitalization and breakthroughs in technology, improving internet connectivity through 4G and 5G, more convenient as the majority of women hesitate to interact with the doctor in person while inflicted with such sickness. Furthermore, online platforms such as Tata 1Mg and Pharm-Easy are incorporating strategies that ask the users to be a part of a program or plan, which allows them to take benefits up to 20-25% cashback and free delivery amongst many.
Vulvodynia Treatment Market Segment Analysis-By Geography
The Vulvodynia Treatment based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36%of the overall market in 2021. The growth in this segment is owing to the factors such as increasing cases of ailment, state-of-the-art health infrastructure, affluent economy ensuing into superfluity of hard cash into research and development of new medicines and techniques, commonness, and comfortableness in discussing such issues in public forums. In addition to that, the North American segment is estimated to offer lucrative growth opportunities to marketers over the forecast period 2022-2027. The growth is owing to factors such as ballooning genital infections, and skin infections, soaring medical industry, more awareness in patients compare to anywhere in the world. Additionally, predominant manufacturers such as Incyte and GSK are part of 20-25% of their revenue for medical development and enhancements.
Vulvodynia Treatment Market Drivers
Soaring cases of Vulvodynia is Projected to Drive Market Growth.
Sicknesses like Vulvodynia has come to the foreground in recent year on an unprecedented scale as a result of the modern lifestyle. Therefore, the soaring prevalence of vulvodynia is one of the foremost factors estimated to escalate the development of the respective market. In an epidemiological study conducted in the US, it is claimed that around 15%-16% of women face complications of vulvodynia once in their lives. Moreover, the percentage is expected to escalate in the future due to the contemporary lifestyles of people which come with tons of problems.
The surfeit of capital expenditure in medical research and development is Expected to Boost Product Demand.
The world we are living in is under the attack of viruses and bacteria. Various contemporary Sicknesses have come into the foreground that doesn’t have any existence in past. Therefore, the government, and various international agencies like WHO have ramped up their efforts along with the drift of capital into the medical sector in order to research and develop various treatments and medicines to brawl with such septicemia which is expected to inflate the demand in Vulvodynia treatment market
Vulvodynia Treatment Market Challenges
Low awareness, Hesitation in discussing such issues is Anticipated to Hamper Market Growth.
Ailments like vulvodynia are increasing in the female faction of society but still, the majority of the population around the globe aren’t cognizant about the same or turning a blind eye to it because they consider it obscene to debate such problems in public forums. Population living in pastoral and underdeveloped areas are oblivious to such complications. On top of that, there is not a sure-fire remedy to treat this illness which is going to hamper the progress of the vulvodynia treatment market.
Vulvodynia Treatment Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in this market. Vulvodynia Treatment top 10 companies include:
- Sanofi
- Eli Lilly and Company
- Noven Pharmaceuticals
- Pfizer
- Depomed Inc.
- Allergan LLC
- Ipsen Pharma
- GlaxoSmithKline Plc.
- AstraZeneca Plc
- Johnson & Johnson
Partnerships/Product Launches:
On January 11, 2019, Ipsen Pharma demonstrated a leadership position in neurotoxin research with a strong presence at TOXINS 2019. Ipsen has also announced spending $1 billion on its pipeline products which include Phase II trials in hallux abducto valgus and vulvodynia.
Relevant Links:
Report Code: HCR 0120
1. Vulvodynia Treatment Market Overview
1.1 Definitions and Scope
2. Vulvodynia Treatment Market- Executive Summary
3. Vulvodynia Treatment Market– Market Landscape
3.1 Company Benchmarking- Key Companies
3.2 Key Company Financial Analysis
3.3 Market Share Analysis
3.4 Patent Analysis
3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Vulvodynia Treatment Market– Startup Company Scenario (Premium)
4.1 Investment
4.2 Revenue
4.3 Venture Capital and Funding Scenario
5. Vulvodynia Treatment Market– Industry Market Entry Scenario Premium (Premium)
5.1 Regulatory Scenario
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Vulvodynia Treatment Market- Market Forces
6.1 Market Drivers
6.2 Market Constraints
6.3 Porters five force model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Vulvodynia Treatment Market– By Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle Analysis
8. Vulvodynia Treatment Market- By Drug Type (Market Size –$Million/$Billion)
8.1 SNRI (=serotonin-norepinephrine reuptake inhibitors)
8.2 Anesthetic
8.3 Anticonvulsants
8.4 Nerve Block
8.5 Tricyclic Antidepressants
8.6 local anesthetics
8.7 Hormone creams
8.8 Antimicrobials.
9. Vulvodynia Treatment Market- By Buyer/End User (Market Size –$Million/$Billion)
9.1 Hospitals
9.2 Health Centers
9.3 local medical stores
9.4 retail Pharmacies
9.5 Online pharmacies
10. Vulvodynia Treatment Market– By Administrable Mode (Market Size –$Million/$Billion)
10.1 External mode/Topical
10.2 Oral
10.3 Injectable
11. Vulvodynia Treatment Market- By Geography (Market Size -$Million/Billion)
11.1 North America
11.1.1 U.S
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 UK
11.2.4 Italy
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 Japan
11.3.3 South Korea
11.3.4 India
11.3.5 Australia & New Zealand
11.3.6 Rest of Asia-Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Chile
11.4.4 Colombia
11.4.5 Rest of South America
11.5 Rest of World
11.5.1 Middle East
11.5.2 Africa
12. Vulvodynia Treatment Market- Market Entropy
12.1 New product launches
12.2 M&A's, collaborations, JVs, and partnerships
13. Vulvodynia Treatment Market– Industry Competition Landscape (Premium)
13.1 Market Share Analysis
13.1.1 Global Market Share – Key Companies
13.1.2 Market Share by Region – Key Companies
13.1.3 Market Share by Countries – Key Companies
13.2 Competition Matrix
13.3 Best Practices for Companies
14. Vulvodynia Treatment Market– Key Company List by Country Premium (Premium)
15. Vulvodynia Treatment Market- Company Analysis
15.1 Company 1
15.2 Company 2
15.3 Company 3
15.4 Company 4
15.5 Company 5
15.6 Company 6
15.7 Company 7
15.8 Company 8
15.9 Company 9
15.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"